# Chronic Graft-versus-host-disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-graft-versus-host-disease

> 12 upcoming FDA catalysts in chronic Graft-versus-host-disease: NIKTIMVO (axatilimab, INCY) on Sep to Dec 2027 (topline data readout); NIKTIMVO (axatilimab, INCY) on September 2027 (primary completion); NIKTIMVO (axatilimab, INCY) on May to Aug 2028 (topline data readout); NIKTIMVO (axatilimab, INCY) on May 2028 (primary completion); and 8 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 1, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Chronic Graft-versus-host-disease | completed | "NCT06388564 (A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-01 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388564)) |
| Sep to Dec 2027 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06585774 (A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585774)) |
| September 2027 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06585774 (A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585774)) |
| May to Aug 2028 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06821542 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06821542)) |
| May 2028 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT06821542 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06821542)) |
| Sep to Dec 2028 | [Belumosudil topline data readout](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT06143891 (A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143891)) |
| Sep to Dec 2028 | [Belumosudil topline data readout](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07116031 (A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07116031)) |
| September 2028 | [Belumosudil primary completion](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07116031 (A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07116031)) |
| September 2028 | [Belumosudil primary completion](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT06143891 (A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143891)) |
| Jan to Apr 2029 | [NIKTIMVO (axatilimab) topline data readout](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT07124078 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07124078)) |
| January 2029 | [NIKTIMVO (axatilimab) primary completion](https://sec-api.dev/pdufa/axatilimab) | INCY | Chronic Graft-versus-host-disease | scheduled | "NCT07124078 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07124078)) |
| Sep to Dec 2029 | [Belumosudil topline data readout](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07771439 (A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07771439)) |
| September 2029 | [Belumosudil primary completion](https://sec-api.dev/pdufa/belumosudil) | SNY | Chronic Graft Versus Host Disease | scheduled | "NCT07771439 (A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07771439)) |

## Drugs

- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [Belumosudil](https://sec-api.dev/pdufa/belumosudil) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-graft-versus-host-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Graft-versus-host-disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-graft-versus-host-disease

```bibtex
@misc{secapidev_indications_chronic_graft_versus_host_disease_20261116,
  title        = {Chronic Graft-versus-host-disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-graft-versus-host-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_graft_versus_host_disease_20261116","title":"Chronic Graft-versus-host-disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-graft-versus-host-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
